Differential Reduction in Monocyte Activation and Vascular Inflammation with Integrase Inhibitor-Based Initial Antiretroviral Therapy among HIV-Infected Individuals

Journal of Infectious Diseases

Volumn 212, Issue 3, 2015, Pages 345-354

  Hileman, Corrilynn O ^a,b   Kinley, Bruce ^c   Scharen Guivel, Valeska ^d   Melbourne, Kathy ^d   Szwarcberg, Javier ^d   Robinson, Janet ^a   Lederman, Michael M ^a,c   McComsey, Grace A ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MetroHealth Medical Center   (Belgium)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

antiretroviral naive; HIV infection; monocyte activation; systemic inflammation; vascular inflammation

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; CD163 ANTIGEN; COBICISTAT; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTEGRASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; TREATMENT DURATION; VASCULITIS; WEIGHT CHANGE; BLOOD; HIV INFECTIONS; IMMUNOLOGY; INFLAMMATION; RANDOMIZED CONTROLLED TRIAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; ANTIGENS, CD14; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; INFLAMMATION; MALE; MONOCYTES;

EID: 84936810526     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv004     Document Type: Article

References (50)

1. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013; 8:e81355.
2. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIVinfected patients in France in 2010 (national survey): Trends since 2000. AIDS 2014; 28:1181-91.
3. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614-22.
4. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12.
5. Marcus JL, LeydenWA, Chao CR, et al. HIV infection and incidence of ischemic stroke. AIDS 2014; 28:1911-9.
6. Petoumenos K, Reiss P, Ryom L, et al. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: A comparison of the D:A: D CVD risk equation and general population CVD risk equations. HIV medicine 2014; 15:595-603.
7. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: Traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19:927-33.
8. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
9. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379-86.
10. Shaked I, Hanna DB, Gleissner C, et al. Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol 2014; 34:1085-92.
11. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: Association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206:1558-67.
12. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
13. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-85.
14. Crane M, Avihingsanon A, Rajasuriar R, et al. Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B Virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy. J Infect Dis 2014; 210:745-51.
15. Naeger DM, Martin JN, Sinclair E, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 2010; 5:e8886.
16. Yurochko AD, Huang ES. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. J Immunol 1999; 162:4806-16.
17. Chun TW, Nickle DC, Justement JS, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115:3250-5.
18. Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 2014; 111:2307-12.
19. Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study. AIDS 2010; 24:1697-707.
20. Ofotokun I, Ribaudo H, Na L, et al. Darunavir or atazanavir vs raltegravir lipid changes are unlinked to ritonavir exposure: ACTG 5257 [abstract 746]. In: Program and abstracts of the 21st Conference on Retroviruses and Opportunistic Infections (Boston). San Francisco: International Antiviral Society-USA. 2014; 485-6.
21. Patterson KB, Prince HA, Stevens T, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS 2013; 27:1413-9.
22. Nordell AD, McKenna M, Borges AH, Duprez D, Neuhaus J, Neaton JD. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014; 3:e000844.
23. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210:1228-38.
24. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439-48.
25. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-36.
26. Longenecker CT, Jiang Y, Orringer CE, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014; 28:969-77.
27. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119-27.
28. Sandler NG,Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality inHIV infection. J Infect Dis 2011; 203:780-90.
29. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-44.
30. Henry K, Kitch D, Dube M, et al. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS 2004; 18:2434-7.
31. Shikuma CM, Ribaudo HJ, Zheng Y, et al. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses 2011; 27:461-8.
32. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIVinfected patients after initiation of antiretroviral therapy. Diabetes Care 2010; 33:2244-9.
33. Hattab S, Guihot A, Guiguet M, et al. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: An observational study. BMC Infect Dis 2014; 14:122.
34. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554-61.
35. McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012; 26:1371-85.
36. Taiwo B, Matining RM, Zheng L, et al. Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. J Antimicrob Chemother 2013; 68:1857-61.
37. Funderburg NT, Andrade A, Chan ES, et al. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naive patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. PLoS One 2013; 8:e83514.
38. Kelesidis T, Trann TTT, McComsey GA, et al. Comparison of effects of ATV, RAL or DRV with FTC/tenofovir on biomarkers of systemic inflammation, macrophage and T-cell activation: ACTG A5260s. International AIDS Conference. Melbourne, Australia, 2014.
39. Martinez E, D'Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavirboosted protease inhibitors to raltegravir. AIDS 2012; 26:2315-26.
40. Silva EF, Charreau I, Gourmel B, et al. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis 2013; 208:892-7.
41. Lake J, McComsey G, Hulgan T, et al. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: The Women, Integrase and Fat Accumulation Trial. HIV medicine 2014; 15:431-41.
42. Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 2012; 120:4599-608.
43. Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999; 19:2909-17.
44. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25:923-31.
45. Sabatine MS, Morrow DA, O'Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27:2463-9.
46. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008; 101:51F-7.
47. Horkko S, Binder CJ, Shaw PX, et al. Immunological responses to oxidized LDL. Free Radic Biol Med 2000; 28:1771-9.
48. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:1876-90.
49. Samson S, Mundkur L, Kakkar VV. Immune response to lipoproteins in atherosclerosis. Cholesterol 2012; 2012:571846.
50. De Pablo-Bernal RS, Ruiz-Mateos E, Rosado I, et al. TNF-alpha levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects. J Antimicrob Chemother 2014; 69:3041-6.